Literature DB >> 24249722

Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study.

Enayet K Chowdhury1, Alice Owen, Zanfina Ademi, Henry Krum, Colin I Johnston, Lindon M H Wing, Mark R Nelson, Christopher M Reid.   

Abstract

BACKGROUND: We sought to determine the incidence of newly diagnosed diabetes in treated elderly hypertensive patients and the prognostic impact of diabetes on long-term survival.
METHODS: The Second Australian National Blood Pressure (ANBP2) study randomized 6,083 hypertensive patients aged 65-84 years to angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic-based therapy and followed them for a median of 4.1 years. Long-term survival was determined in 5,678 patients over an additional median of 6.9 years after ANBP2 (post-trial).
RESULTS: After ANBP2, the cohort was classified into preexisting (7.2%), newly diagnosed (5.6%), and no diabetes (87.2%) groups. A 44% higher incidence of newly diagnosed diabetes was observed in patients randomized to thiazide diuretic compared with ACEI-based treatment. The other predictors of newly diagnosed diabetes were having a higher body mass index, having a higher random blood glucose, and living in a regional location compared to major cities (a geographical classification based on accessibility) at study entry. After completion of ANBP2, compared with those with no diabetes, the preexisting diabetes group experienced higher cardiovascular (hazards ratio (HR) = 1.65; 95% confidence interval (CI) = 1.03-2.65) and all-cause mortality (HR = 1.40; 95% CI = 1.02-1.92) when adjusted for age, sex, and treatment. A similar pattern was observed after including the post-trial period for cardiovascular (HR = 1.52; 95% CI = 1.20-1.93) and all-cause mortality (HR = 1.50; 95% CI = 1.29-1.73). However, when the newly diagnosed group was compared with the no diabetes group, no significant difference was observed in cardiovascular (HR = 0.33; 95% CI = 0.11-1.05) or all-cause mortality (HR = 0.76; 95% CI = 0.47-1.23) either during the ANBP2 trial or including post-trial follow-up (cardiovascular: HR = 0.82; 95% CI = 0.58-1.17; all-cause mortality: HR = 1.04; 95% CI = 0.85-1.27).
CONCLUSIONS: Long-term presence of diabetes reduces survival. Compared with thiazide diuretics, ACEI-based antihypertensives may delay the development of diabetes in those at risk and thus potentially improve cardiovascular outcome in the elderly.

Entities:  

Keywords:  blood pressure; elderly; hypertension; mortality; newly diagnosed diabetes; preexisting diabetes.

Mesh:

Substances:

Year:  2013        PMID: 24249722     DOI: 10.1093/ajh/hpt212

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: A network meta-analysis.

Authors:  Zimeng Li; Yi Li; Yulong Liu; Wenbo Xu; Qing Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-10-25       Impact factor: 3.738

2.  Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity.

Authors:  Enayet K Chowdhury; Zanfina Ademi; John R Moss; Lindon M H Wing; Christopher M Reid
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

Review 3.  Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.

Authors:  Sripal Bangalore; Robert Fakheri; Bora Toklu; Franz H Messerli
Journal:  BMJ       Date:  2016-02-11

4.  Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis.

Authors:  Yang Yang; Huilan Xu
Journal:  J Cell Mol Med       Date:  2017-02-23       Impact factor: 5.310

Review 5.  Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function.

Authors:  Yeoree Yang; Ji-Won Kim; Heon-Seok Park; Eun-Young Lee; Kun-Ho Yoon
Journal:  J Diabetes Investig       Date:  2020-01-24       Impact factor: 4.232

6.  The Influence of Diabetes Mellitus on the Risks of End-Stage Kidney Disease and Mortality After Liver Transplantation.

Authors:  Chung-Ying Lee; Mei-Yi Wu; Hsiu-Chen Chan; Tzu-Ting Chen; Le-Yin Hsu; Mai-Szu Wu; Yih-Giun Cherng
Journal:  Transpl Int       Date:  2022-02-07       Impact factor: 3.782

7.  Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.

Authors:  Stefanie Lip; Panniyammakal Jeemon; Linsay McCallum; Anna F Dominiczak; Gordon T McInnes; Sandosh Padmanabhan
Journal:  Eur Heart J       Date:  2015-10-27       Impact factor: 29.983

8.  First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

Authors:  Yu Jie Chen; Liang Jin Li; Wen Lu Tang; Jia Yang Song; Ru Qiu; Qian Li; Hao Xue; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2018-11-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.